Rare diseases

Authorized indications:

TOBI® is indicated in patients 6 years of age and older with cystic fibrosis (CF) for the long-term treatment of chronic pulmonary infections due to pseudomonas aeruginosa.

Authorized indications:

TOBI Podhaler® is indicated in patients 6 years of age and older with cystic fibrosis (CF) for the long-term treatment of chronic pulmonary infections due to pseudomonas aeruginosa.

Authorized indications:

ZOTEON® is indicated in patients 6 years of age and older with cystic fibrosis (CF) for the long-term treatment of chronic pulmonary infections due to pseudomonas aeruginosa.

Authorized indications:

ZOTEON Podhaler® is indicated in patients 6 years of age and older with cystic fibrosis (CF) for the long-term treatment of chronic pulmonary infections due to pseudomonas aeruginosa.

Authorized indications:

Teglutik® is indicated to extend life or time to mechanical ventilation in patients with amyotrophic lateral sclerosis (ALS). Clinical trials have demonstrated that riluzole extends survival for patients with ALS. Survival was defined as patients who were alive, without intubation for mechanical ventilation, and tracheotomy-free. There is no evidence that riluzole exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms. In late stages of ALS, riluzole has not been shown to be effective. The safety and efficacy of riluzole have only been studied in ALS. Therefore, riluzole should not be used in patients with other form of motor neuron diseases.

Spanish industry